Jul 10, 2024
Twice before WaveData to have looked into this subject only to find there is no link between product value and the delay in the introduction of Category M. However, time moves on, so we thought we’d repeat the analysis, partly because of a recent client request, and...
Jun 18, 2024
Prompted by a Client’s questions about Category M and the formula that goes behind it to drive Pharmacy profitability, we asked Charles Joynson, WaveData MD, to have a closer look at Category M to see if he can make any sense of it. Initially that we assumed that the...
May 15, 2024
The current Ozempic shortage has been driven by the increase in demand as the drug is being used to treat obese patients for long term weight management, in addition to the original group of type 2 diabetes patients. A study run by the University College London (UCL),...
Nov 9, 2023
It would seem sensible to assume that profitable products are less likely to suffer shortages, concessions and price spikes than products where profit is hard to come by. Charles Joynson, WaveData MD, compared the reimbursement price and the average market price for...
Sep 20, 2023
Charles Joynson, WaveData MD, puts a spotlight on Lustral Tabs as we explore the product lifecycle post LOE. Before generics were launched in November 2005 there was a high degree of similarity between the price of the UK and PI (parallel import) packs of Lustral Tabs...
Aug 24, 2023
Normally we expect branded devices to maintain their pharmacy purchase prices over long periods of time. However, here this is not the case. Charles Joynson, WaveData MD investigates further. Looking at the long term market price trends of Freestyle Optium Test Strips...
